KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 93 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $96 | +1820.0% | 9,959 | +1860.4% | 0.00% | – |
| Q2 2023 | $5 | -94.0% | 508 | -95.2% | 0.00% | – |
| Q1 2023 | $83 | -26.5% | 10,608 | -36.8% | 0.00% | – |
| Q4 2022 | $113 | -100.0% | 16,787 | -0.2% | 0.00% | – |
| Q3 2022 | $244,000 | +47.9% | 16,819 | +0.4% | 0.00% | – |
| Q2 2022 | $165,000 | -33.5% | 16,755 | -0.3% | 0.00% | – |
| Q1 2022 | $248,000 | +47.6% | 16,810 | +32.7% | 0.00% | – |
| Q4 2021 | $168,000 | -51.7% | 12,663 | -36.5% | 0.00% | – |
| Q3 2021 | $348,000 | -64.7% | 19,947 | -51.5% | 0.00% | -100.0% |
| Q2 2021 | $985,000 | +13.9% | 41,096 | +22.1% | 0.00% | 0.0% |
| Q1 2021 | $865,000 | +279.4% | 33,659 | +180.5% | 0.00% | – |
| Q4 2020 | $228,000 | +51.0% | 12,000 | 0.0% | 0.00% | – |
| Q3 2020 | $151,000 | +4.1% | 12,000 | 0.0% | 0.00% | – |
| Q2 2020 | $145,000 | +57.6% | 12,000 | 0.0% | 0.00% | – |
| Q1 2020 | $92,000 | -57.0% | 12,000 | 0.0% | 0.00% | – |
| Q4 2019 | $214,000 | +54.0% | 12,000 | 0.0% | 0.00% | – |
| Q3 2019 | $139,000 | -47.7% | 12,000 | 0.0% | 0.00% | – |
| Q2 2019 | $266,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |